Gemini Therapeutics (GMTX) News Today $63.50 +0.96 (+1.53%) (As of 11/21/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Gemini Therapeutics (NASDAQ:GMTX) Enters Controlled Equity Offering AgreementNovember 17, 2024 | americanbankingnews.comWhat Is Gemini? Everything You Should Know About Google's AI ToolOctober 17, 2024 | cnet.comGemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?July 22, 2024 | businessinsider.comGoogle's public release of Gemini 1.5 should build trust, Deutsche Bank saysApril 17, 2024 | seekingalpha.comGemini Therapeutics (NASDAQ:GMTX) Hits New 1-Year High at $32.55Gemini Therapeutics (NASDAQ:GMTX) Reaches New 12-Month High at $32.55April 15, 2024 | marketbeat.comGemini Therapeutics (NASDAQ:GMTX) Sets New 1-Year High at $31.92Gemini Therapeutics (NASDAQ:GMTX) Hits New 1-Year High at $31.92April 8, 2024 | marketbeat.comGemini Therapeutics (NASDAQ:GMTX) Reaches New 1-Year High at $35.40Gemini Therapeutics (NASDAQ:GMTX) Hits New 12-Month High at $35.40April 1, 2024 | marketbeat.comGemini Therapeutics (NASDAQ:GMTX) Sets New 1-Year High at $60.96Gemini Therapeutics (NASDAQ:GMTX) Hits New 52-Week High at $60.96March 25, 2024 | marketbeat.comGemini Therapeutics (NASDAQ:GMTX) Hits New 12-Month High at $67.76Gemini Therapeutics (NASDAQ:GMTX) Sets New 1-Year High at $67.76March 19, 2024 | marketbeat.comGemini Therapeutics (NASDAQ:GMTX) Hits New 52-Week High at $66.32Gemini Therapeutics (NASDAQ:GMTX) Hits New 1-Year High at $66.32March 13, 2024 | marketbeat.comGoogle takes down Gemini AI image generator. Here’s what you need to know.February 26, 2024 | washingtonpost.com‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiascoFebruary 26, 2024 | nypost.com(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson FistelJune 24, 2023 | benzinga.comBronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Gemini Therapeutics, Inc. (GMTX) InvestigationJune 1, 2023 | barrons.comGemini Therapeutics, Inc. (NASDAQ:GMTX) Shares Sold by Ergoteles LLCErgoteles LLC lowered its position in shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX - Get Rating) by 13.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 92,200 shares of the company's stock after selling 13,900 shares durinMarch 8, 2023 | marketbeat.comAssenagon Asset Management S.A. Acquires 66,467 Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX)Assenagon Asset Management S.A. raised its holdings in Gemini Therapeutics, Inc. (NASDAQ:GMTX - Get Rating) by 423.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 82,171 shares of the company's stockJanuary 19, 2023 | marketbeat.comThe Winklevoss' Gemini terminates its yield product as dispute between the crypto exchange and DCG escalatesJanuary 13, 2023 | markets.businessinsider.comGemini HoroscopeJanuary 1, 2023 | usatoday.comDisc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic ProtoporphyriaDecember 27, 2022 | finance.yahoo.comDisc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)October 31, 2022 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, PBFX, EVOP, GMTXSeptember 27, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFYSeptember 26, 2022 | benzinga.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMTX, RMED, LOTZSeptember 16, 2022 | markets.businessinsider.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, DRE, PLD, GMTX, SAFESeptember 6, 2022 | markets.businessinsider.comThe M&A Class Action Firm Announces the Investigation of Gemini Therapeutics, Inc. – GMTXAugust 25, 2022 | apnews.comSHAREHOLDER ALERT: Weiss Law Reminds, LOTZ, GMTX, AAWW, and CCXI Shareholders About Its Ongoing InvestigationsAugust 24, 2022 | benzinga.comGEMINI THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GMTX and Encourages Investors to Contact the FirmAugust 12, 2022 | apnews.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Gemini Therapeutics, Inc. MergerAugust 12, 2022 | marketwatch.comSHAREHOLDER ALERT: Weiss Law Investigates Gemini Therapeutics, Inc.August 11, 2022 | benzinga.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZAugust 11, 2022 | apnews.comGMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to ShareholdersAugust 11, 2022 | apnews.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Gemini Therapeutics, Inc. (Nasdaq – GMTX)August 10, 2022 | apnews.comBlood disorder startup goes public by merging with embattled biotechAugust 10, 2022 | finance.yahoo.comGemini stock soars 35% on merger with Disc Medicine in all-stock dealAugust 10, 2022 | seekingalpha.comGemini Therapeutics, Disc Medicine Announce All-stock MergerAugust 10, 2022 | nasdaq.comGemini Therapeutics and Disc Medicine Announce Merger AgreementAugust 10, 2022 | finance.yahoo.comTrading was temporarily halted for "GMTX" at 07:08 AM with a stated reason of "News pending."August 10, 2022 | marketbeat.comInsider Buying: Braden Leonard Just Spent US$75k On Gemini Therapeutics, Inc. (NASDAQ:GMTX) SharesApril 15, 2022 | finance.yahoo.comGemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?April 12, 2022 | finance.yahoo.comHC Wainwright Lowers Gemini Therapeutics (NASDAQ:GMTX) to NeutralHC Wainwright cut Gemini Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday.March 11, 2022 | marketbeat.comGemini Therapeutics GAAP EPS of -$1.78 beats by $0.17March 10, 2022 | seekingalpha.comGemini Therapeutics Reports 2021 Financial ResultsMarch 10, 2022 | finance.yahoo.comGemini Therapeutics (NASDAQ:GMTX) Upgraded to "Buy" by Zacks Investment ResearchZacks Investment Research raised Gemini Therapeutics from a "hold" rating to a "buy" rating and set a $1.50 price target for the company in a report on Monday.March 7, 2022 | marketbeat.comWhat 5 Analyst Ratings Have To Say About Gemini TherapeuticsMarch 3, 2022 | benzinga.comTwo more Cambridge biotechs cutting staffMarch 2, 2022 | bizjournals.comAPi Group Shares Slide After Q4 Results, Clocks 27% Revenue GrowthMarch 1, 2022 | uk.investing.comJefferies Downgrades Gemini Therapeutics to Hold, Lowers Price Target to $1.5March 1, 2022 | benzinga.comGemini extends losses as strategic review prompts Jefferies downgradeMarch 1, 2022 | seekingalpha.comGemini Therapeutics names interim CEO, announces job cutsFebruary 28, 2022 | seekingalpha.comGemini Therapeutics Provides Corporate UpdateFebruary 28, 2022 | finance.yahoo.com Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price. Click here for the ticker >>> GMTX Media Mentions By Week GMTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMTX News Sentiment▼0.000.49▲Average Medical News Sentiment GMTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMTX Articles This Week▼10▲GMTX Articles Average Week Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Catalent News Sarepta Therapeutics News Qiagen News Revolution Medicines News Intra-Cellular Therapies News Roivant Sciences News Ascendis Pharma A/S News Legend Biotech News Elanco Animal Health News Blueprint Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMTX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GMTX Stock Alerts